Evox populates its pipeline

Why exosome therapeutics play Evox is focusing first on rare diseases

As Evox Therapeutics Ltd. continues to refine the platform with which it develops exosome-based therapeutics, the company plans to use its £35.5 million ($45.9 million) series B round to start clinical trials on as many as three rare disease therapies in its pipeline.

Oxford, U.K.-based Evox is developing exosome therapies that use specially engineered versions of the extracellular vesicles to ferry therapeutic cargoes to

Read the full 636 word article

User Sign In